

NETT NewsFlash

October 2011



Enrollment Update:
As of 10-27-11 at 12p (EDT)

ALIAS

ProTECT

point

<i>Arizona</i>	5	19	6
<i>Cincinnati</i>	26	44	20
<i>Emory</i>	24	38	10
<i>HFH</i>	11	6	21
<i>Kentucky</i>	28	11	17
<i>Maryland</i>	12	<5	10
<i>Minnesota</i>	19	31	16
<i>NYP</i>	24	<5	12
<i>OHSU</i>	48*	13	11
<i>Stanford</i>	19	34	15
<i>Temple</i>	23	19	15
<i>Texas</i>	30	40	12
<i>UCSF</i>	20	12	11
<i>UPenn</i>	33	25	45
<i>VCU</i>	10	8	5
<i>Wayne State</i>	22	7	39
<i>Wisconsin</i>	8	48	12
TOTAL	362	357	277

*OHSU WAS AN ORIGINAL SITE IN THE ALIAS I TRIAL AND CONTINUES IN THE ALIAS II TRIAL UNDER THE SAME CONTRACTUAL ARRANGEMENT WITH THE UNIVERSITY OF MIAMI STUDY CHAIR SITE.

POINT & ProTECT: Randomization Issues

Randomization problems have occurred for POINT and ProTECT when subjects receive a different drug kit than that to which they were assigned. This is a critical problem in Intention to Treat trials since the subjects remain in the group to which they were initially assigned (via by WebDCU or the hotline instructions), regardless of the actual treatment received. Too many of these types of errors can dilute the effect of our research or create a false positive result.

To avoid further drug assignment errors, please ensure that all study team members are fully trained on randomization procedures. In addition, it is critical that the study coordinators/investigators and/or pharmacists verify that the drug kit number assigned (via by WebDCU or the hotline instructions) matches the drug kit dispensed.

NETT Network

Contact Us: nett-contact@umich.edu (734) 232-2142 Website: <http://nett.umich.edu>